Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Nov. 3, 2021—Lighthouse Lab Services announced that the FDA has granted emergency use authorization for its CovidNow SARS-CoV-2 assay kit. The EUA covers use for symptomatic and asymptomatic patients with a provider’s order.
Nov. 1, 2021—Bio-Rad Laboratories launched an enhanced version of its Liquichek Diabetes Control.
Oct. 29, 2021—Hologic announced that its Aptima SARS-CoV-2/Flu assay is available for the simultaneous detection and differentiation of three respiratory viruses that can present with overlapping clinical symptoms.
Oct. 27, 2021—Bio-Rad Laboratories launched its CFX Opus 96 Dx and CFX Opus 384 Dx systems, real-time PCR detection systems that have been listed with the FDA for IVD testing and that meet the CE-IVD requirement for IVD use in Europe.
Oct. 25, 2021—Labcon North America, a wholly owned subsidiary of Helena Laboratories, has announced a $59.3 million contract award from the U.S. Department of Defense in coordination with the U.S. Department of Health and Human Services.
Oct. 21, 2021—Hardy Diagnostics has released its HardyChrom Candida + auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species.
Oct. 18, 2021—LumiraDx has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the Food and Drug Administration for emergency use authorization.
Oct. 15, 2021—Beckman Coulter launched at this year’s AACC Annual Scientific Meeting and Clinical Lab Expo its DxU Iris Workcell, a fully automated system designed for high-volume laboratories that streamlines urinalysis workflow and reduces manual reviews to four percent.
Oct. 13, 2021—PerkinElmer announced that the FDA has issued emergency use authorization for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.
Oct. 11, 2021—Bio-Rad announced its Exact Diagnostics RP Positive Run Control for syndromic respiratory panels is now available with inactivated whole virus for SARS-CoV-2.
